Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Return on Capital (ROC)

Microsoft Excel

Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.


Return on Invested Capital (ROIC)

Abiomed Inc., ROIC calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1 140,811 259,982 239,725 253,605 159,878 79,888
Invested capital2 693,367 737,876 594,867 497,537 273,719 226,723
Performance Ratio
ROIC3 20.31% 35.23% 40.30% 50.97% 58.41% 35.24%
Benchmarks
ROIC, Competitors4
Abbott Laboratories 10.96% 11.30% — — — —
Elevance Health Inc. 10.24% 11.26% — — — —
Intuitive Surgical Inc. 22.01% 37.63% — — — —
Medtronic PLC 7.02% 5.59% — — — —
UnitedHealth Group Inc. 13.68% 13.51% — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 140,811 ÷ 693,367 = 20.31%

4 Click competitor name to see calculations.


Between March 31, 2017, and March 31, 2022, the company experienced significant growth in its operational scale and invested capital, although this expansion was accompanied by a long-term decline in capital efficiency following a peak in 2018.

Net Operating Profit After Taxes (NOPAT) Performance
A period of rapid growth is observed from 2017 to 2019, with NOPAT increasing from US$ 79.89 million to US$ 253.61 million. This figure remained relatively stable between 2019 and 2021, peaking at US$ 259.98 million in 2021. However, a sharp contraction occurred in 2022, with NOPAT falling to US$ 140.81 million.
Invested Capital Trajectory
Invested capital exhibited a consistent upward trend for the majority of the period, rising from US$ 226.72 million in 2017 to a peak of US$ 737.88 million in 2021. This indicates a substantial increase in the deployment of resources into the business. A slight decrease to US$ 693.37 million was recorded in the final year of the analysis.
Return on Invested Capital (ROIC) Analysis
ROIC peaked in 2018 at 58.41%, signifying a period of exceptional capital efficiency. Subsequently, a persistent downward trend is observed, with the ratio falling to 40.30% in 2020, 35.23% in 2021, and reaching a period low of 20.31% in 2022. The decline in ROIC, occurring while invested capital was largely increasing, suggests that the incremental capital deployed did not generate proportional increases in operating profit.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Decomposition of ROIC

Abiomed Inc., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Mar 31, 2022 20.31% = 18.62% × 1.49 × 73.15%
Mar 31, 2021 35.23% = 34.40% × 1.16 × 88.63%
Mar 31, 2020 40.30% = 30.90% × 1.42 × 91.97%
Mar 31, 2019 50.97% = 34.47% × 1.55 × 95.45%
Mar 31, 2018 58.41% = 27.68% × 2.19 × 96.54%
Mar 31, 2017 35.24% = 20.92% × 1.97 × 85.43%

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


The return on invested capital (ROIC) exhibited a significant peak followed by a sustained decline over the analyzed six-year period. Starting at 35.24% in 2017, ROIC reached a maximum of 58.41% in 2018 before contracting to 20.31% by March 31, 2022.

Operating Profit Margin (OPM)
A positive trend in profitability was observed between 2017 and 2019, with margins expanding from 20.92% to a peak of 34.47%. This efficiency remained relatively stable through 2021. However, a sharp contraction occurred in 2022, where the margin fell to 18.62%, representing the lowest level in the recorded period and serving as a primary driver for the decline in overall return.
Turnover of Capital (TO)
Capital efficiency peaked in 2018 at a ratio of 2.19 but entered a period of consistent decline thereafter, reaching a low of 1.16 in 2021. While a slight recovery to 1.49 was noted in 2022, the overall trend indicates an increase in the invested capital base relative to revenue generation, which dampened the ROIC during the intermediate years despite strong margins.
Effective Cash Tax Rate (1 – CTR)
The tax efficiency component remained high for much of the period, peaking at 96.54% in 2018. A gradual downward trend followed, culminating in a decrease to 73.15% by 2022. This indicates an increased effective cash tax burden in the final year, further compressing the net return on capital.

The decomposition reveals that the peak ROIC in 2018 was the result of a simultaneous optimization of profit margins, capital turnover, and tax efficiency. The subsequent erosion of ROIC was initially driven by declining capital turnover between 2019 and 2021, and was ultimately accelerated in 2022 by a simultaneous collapse in operating margins and a reduction in tax efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Operating Profit Margin (OPM)

Abiomed Inc., OPM calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1 140,811 259,982 239,725 253,605 159,878 79,888
Add: Cash operating taxes2 51,674 33,340 20,943 12,089 5,738 13,626
Net operating profit before taxes (NOPBT) 192,485 293,322 260,668 265,694 165,616 93,514
 
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
Add: Increase (decrease) in deferred revenue 2,040 5,175 2,754 1,423 4,475 1,717
Adjusted revenue 1,033,793 852,697 843,637 770,855 598,224 447,021
Profitability Ratio
OPM3 18.62% 34.40% 30.90% 34.47% 27.68% 20.92%
Benchmarks
OPM, Competitors4
Abbott Laboratories 20.24% 20.37% — — — —
Elevance Health Inc. 5.64% 6.58% — — — —
Intuitive Surgical Inc. 26.19% 33.56% — — — —
Medtronic PLC 19.15% 16.48% — — — —
UnitedHealth Group Inc. 9.13% 8.33% — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted revenue
= 100 × 192,485 ÷ 1,033,793 = 18.62%

4 Click competitor name to see calculations.


The financial trajectory from 2017 to 2022 is characterized by consistent revenue expansion coupled with significant volatility in operating profitability and margins.

Revenue Growth
Adjusted revenue demonstrated a continuous upward trend over the six-year period, growing from 447.02 million in 2017 to 1.03 billion in 2022. This indicates a steady increase in the scale of operations.
Net Operating Profit Before Taxes (NOPBT)
NOPBT experienced substantial growth from 2017 to 2021, rising from 93.51 million to a peak of 293.32 million. However, a sharp reversal occurred in 2022, with NOPBT falling to 192.49 million, despite the record high revenue achieved in that same year.
Operating Profit Margin (OPM)
The operating profit margin exhibited a period of expansion, rising from 20.92% in 2017 to a peak of 34.47% in 2019. After maintaining a relative plateau between 30.90% and 34.40% from 2019 to 2021, the margin contracted severely in 2022 to 18.62%, marking the lowest efficiency level in the reported timeframe.

The analysis reveals a divergence in 2022, where revenue growth failed to translate into operating profit. The precipitous drop in the operating profit margin during the final year suggests a significant increase in operating costs or a shift in the cost structure that offset the gains from higher sales volume.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Turnover of Capital (TO)

Abiomed Inc., TO calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 1,031,753 847,522 840,883 769,432 593,749 445,304
Add: Increase (decrease) in deferred revenue 2,040 5,175 2,754 1,423 4,475 1,717
Adjusted revenue 1,033,793 852,697 843,637 770,855 598,224 447,021
 
Invested capital1 693,367 737,876 594,867 497,537 273,719 226,723
Efficiency Ratio
TO2 1.49 1.16 1.42 1.55 2.19 1.97
Benchmarks
TO, Competitors3
Abbott Laboratories 0.71 0.69 — — — —
Elevance Health Inc. 2.33 2.14 — — — —
Intuitive Surgical Inc. 1.16 1.27 — — — —
Medtronic PLC 0.46 0.42 — — — —
UnitedHealth Group Inc. 1.95 2.04 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Invested capital. See details »

2 2022 Calculation
TO = Adjusted revenue ÷ Invested capital
= 1,033,793 ÷ 693,367 = 1.49

3 Click competitor name to see calculations.


The analysis of the financial data from 2017 to 2022 reveals a period of substantial growth in both revenue and invested capital, resulting in a fluctuating turnover of capital ratio. While revenue grew consistently throughout the period, the pace of capital investment varied, which directly impacted the efficiency of capital utilization.

Adjusted Revenue Trends
Adjusted revenue demonstrated a continuous upward trend, increasing from 447,021 thousand US$ in 2017 to 1,033,793 thousand US$ in 2022. The most significant growth occurred between 2017 and 2019, followed by a period of relative stabilization between 2020 and 2021, and a sharp increase in the final fiscal year.
Invested Capital Evolution
Invested capital expanded significantly over the analyzed period, rising from 226,723 thousand US$ in 2017 to a peak of 737,876 thousand US$ in 2021. A notable surge in capital deployment occurred between 2018 and 2019, where the investment nearly doubled. However, a slight contraction in invested capital was observed in 2022, decreasing to 693,367 thousand US$.
Turnover of Capital (TO) Analysis
The turnover of capital ratio exhibited a peak of 2.19 in 2018 before entering a downward trend that lasted until 2021, reaching a minimum of 1.16. This decline indicates that during this interval, the growth in invested capital outpaced the growth in adjusted revenue, leading to a decrease in asset productivity. In 2022, the ratio rebounded to 1.49, driven by the combination of record revenue growth and a reduction in the invested capital base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Effective Cash Tax Rate (CTR)

Abiomed Inc., CTR calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1 140,811 259,982 239,725 253,605 159,878 79,888
Add: Cash operating taxes2 51,674 33,340 20,943 12,089 5,738 13,626
Net operating profit before taxes (NOPBT) 192,485 293,322 260,668 265,694 165,616 93,514
Tax Rate
CTR3 26.85% 11.37% 8.03% 4.55% 3.46% 14.57%
Benchmarks
CTR, Competitors4
Abbott Laboratories 23.97% 20.05% — — — —
Elevance Health Inc. 22.01% 20.22% — — — —
Intuitive Surgical Inc. 27.40% 11.76% — — — —
Medtronic PLC 19.53% 18.59% — — — —
UnitedHealth Group Inc. 23.25% 20.32% — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 51,674 ÷ 192,485 = 26.85%

4 Click competitor name to see calculations.


The effective cash tax rate (CTR) exhibited significant volatility between March 31, 2017, and March 31, 2022, characterized by an initial sharp decline followed by a sustained and accelerating upward trend. While operating profitability grew substantially for much of the period, the cash tax burden increased at a disproportionate rate in the latter years.

Effective Cash Tax Rate (CTR) Trajectory
The CTR began at 14.57% in 2017 before dropping to a period low of 3.46% in 2018. From 2019 through 2022, the rate increased consistently each year, progressing to 4.55%, 8.03%, 11.37%, and ultimately peaking at 26.85%. This trajectory indicates a significant increase in the cash tax burden relative to operating profits over the five-year period following 2017.
Cash Operating Taxes Analysis
Cash tax payments demonstrated an aggressive upward trend after 2018. Following a decrease to US$ 5.7 million in 2018, cash taxes rose steadily, exceeding US$ 51.6 million by March 31, 2022. The total cash tax outflow in 2022 was nearly four times the amount paid in 2017, despite the fluctuations in operating profit.
Correlation Between NOPBT and Tax Rates
Net operating profit before taxes (NOPBT) grew from US$ 93.5 million in 2017 to a peak of US$ 293.3 million in 2021. However, in 2022, NOPBT declined to US$ 192.5 million. The convergence of this profit decline with the highest recorded cash tax payment (US$ 51.7 million) resulted in the sharp spike of the CTR to 26.85%. This suggests that tax payments in the final year were not aligned with the current year's operating performance, potentially indicating the exhaustion of prior tax credits or the settlement of deferred tax liabilities.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?